Loading stock analysis…
Evidence Synthesis
Last synthesized: 22 Aug 2026, 00:20
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence Synthesis
Bharat Pharmaceuticals (BALPHARMA) reported a strong quarterly performance, with its gross margin accelerating to 47.5%, up from 5.83%.
The company's marginal operating leverage also increased to , up from 2.16%. However, revenue growth year-over-year decelerated to , down from 44.6%. Additionally, the company's close price declined to , down from 86.66 INR. The daily volume decreased to , down from 49,335 shares.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 47.5 % | 5.83 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 5.83 % | 2.16 | ▲ |
| REVENUE_GROWTH_YOY | 34.5 % | 446.2 | ▼ |
| PRICE_CHANGE_PERCENT | -0.842 % | — | - |
| DAILY_VOLUME | 8,955 shares | 49,335 | ▼ |
| CLOSE_PRICE | 85.93 INR | 86.66 | ▼ |